AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million, Validating Its Tunable Drug Delivery Platform
- AmacaThera receives US$5 million upfront and up to US$225 million in potential future milestone payments with Pacira BioSciences for AMT-143, AmacaThera’s long-acting non-opioid anesthetic for post-operative pain
- AMT-143 leverages AmacaThera’s breakthrough tunable hydrogel platform, delivering sustained local release of ropivacaine
- AmacaThera and Pacira will collaborate on the Phase 2 clinical program, and Pacira will fund clinical development, manufacturing, and commercialization, with the program projected to commence in 2026
- Partnership marks a major validation of AmacaThera’s scalable hydrogel delivery technology and its transformative potential across multiple therapeutic areas
Toronto, Ontario – November 4, 2025 — AmacaThera, a leading developer of next generation hydrogel-based drug delivery solutions that enable precise, tunable, and sustained release to improve a wide range of active therapeutics, today announced an exclusive worldwide licensing agreement with Pacira BioSciences, Inc., a leader in non-opioid pain management, for the development and commercialization of AMT-143, an investigational long-acting non-opioid anesthetic for post-operative pain.
